Keith Michael Sullivan, MD

Professor of Medicine
James B. Wyngaarden Distinguished Professor of Medicine, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address

Research areas

  • Late effects of cancer treatment and stem cell transplantation 
  • Chronic graft-versus-host disease 
  • Transplantation for sickle cell and autoimmune diseases 
  • Knowledge engineering

Early on, Dr. Sullivan and the team at Fred Hutchinson Cancer Research Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT). As a result of this work, it became clear that blood and marrow transplant recipients require systematic long-term follow-up to evaluate and treat late complications of high-dose chemoradiotherapy and SCT.

The program grew into a large multidisciplinary team, resulting in improvement in patient outcome and quality of life. Through the late events project, he also contributed to outcomes research, computer decision support systems, and knowledge engineering for follow-up care. With quality of life as a focus, research pursued the application of SCT to diseases with high morbidity but little immediate mortality. For young patients with advanced, symptomatic sickle cell disease, myeloablative conditioning and SCT from an HLA-identical sibling has led to an 86% long-term survival free of sickle cell disease. For individuals with autoimmune diseases such as multiple sclerosis, scleroderma, and systemic lupus erythematosus, current therapy is often incomplete and significant morbidity from the disease or its treatment is observed.

Recent preclinical and clinical data suggest that high-dose immunosupression and SCT can halt the progression and, in some settings, reverse the course of autoimmune diseases. Since his arrival at Duke University, over 30 centers nationwide are participating in Duke-led phase II and III trials to test the toxicity, efficacy, and quality of life following autologous and allogeneic stem cell transplantation for autoimmune diseases.

These trials will also serve as platforms to study the immune repertoire and mechanistic pathways before and after SCT to gain greater insight into the basic mechanisms of autoimmunity.

A national repository of tissue and cell specimens is also part of these NIH-supported trials to further promote scientific study from these unique patients.

In Their Words

Education and Training

  • M.D., Indiana University at Indianapolis, 1971


McSweeney, P. A., D. E. Furst, R. A. Nash, L. Holmberg, K. McDonagh, L. Crofford, R. Dansey, et al. “High-dose immunosuppressive therapy (HDIT) and autologous stem cell transplant for severe systemic sclerosis (SSc).” Blood 96, no. 11 (November 16, 2000): 844A-844A.


Nash, R. A., R. Dansey, J. Storek, K. M. Sullivan, S. Pavletic, K. T. McDonagh, G. H. Kraft, et al. “Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases.” Blood 96, no. 11 (November 16, 2000): 406A-406A.


Nash, R. A., G. H. Kraft, J. D. Bowen, P. A. McSweeney, S. Pavletic, J. Al-Omaishi, J. R. Corboy, et al. “Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT).” Blood 96, no. 11 (November 16, 2000): 842A-843A.


Furlong, T., R. Storb, C. Anasetti, F. R. Appelbaum, H. J. Deeg, K. Doney, P. Martin, K. Sullivan, R. Witherspoon, and R. A. Nash. “Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.” Bone Marrow Transplantation 26, no. 9 (November 2000): 985–91.

Full Text

Stern, J. M., B. Bruemmer, C. M. Moinpour, K. M. Sullivan, P. Lenssen, and S. N. Aker. “Impact of a randomized, controlled trial of liberal vs conservative hospital discharge criteria on energy, protein, and fluid intake in patients who received marrow transplants.” Journal of the American Dietetic Association 100, no. 9 (September 2000): 1015–22.

Full Text

Walters, M. C., R. Storb, M. Patience, W. Leisenring, T. Taylor, J. E. Sanders, G. E. Buchanan, et al. “Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease.” Blood 95, no. 6 (March 15, 2000): 1918–24.


Walters, M. C., R. Storb, M. Patience, W. Leisenring, T. Taylor, J. E. Sanders, G. E. Buchanan, et al. “Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report.” Blood 95, no. 6 (March 15, 2000): 1918–24.


Kansu, E., and K. M. Sullivan. “Late complications of hematopoietic stem cell transplantation.” In Hematopoietic Stem Cell Transplantation, 413–33, 2000.


Socié, G., R. E. Curtis, H. J. Deeg, K. A. Sobocinski, A. H. Filipovich, L. B. Travis, K. M. Sullivan, et al. “New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.” J Clin Oncol 18, no. 2 (January 2000): 348–57.

Full Text